Jan. 28, 2008 - Medivation, Inc. (Nasdaq: MDVN) announced that, based on its end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), the Company plans to begin a pivotal confirmatory Phase 3 trial of Dimebon(TM) for mild-to-moderate Alzheimer's Disease in the second quarter of 2008... Medivation's Press Release -Monday, January 28, 2008
Medivation, Pivotal Confirmatory Phase 3 Trial of Dimebon(TM) for Alzheimer's Disease in Second Quarter of 2008
Jan. 28, 2008 - Medivation, Inc. (Nasdaq: MDVN) announced that, based on its end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), the Company plans to begin a pivotal confirmatory Phase 3 trial of Dimebon(TM) for mild-to-moderate Alzheimer's Disease in the second quarter of 2008... Medivation's Press Release -
